SAN DIEGO, April 2 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will present at the CIBC World Markets Biotechnology and Specialty Pharmaceuticals Conference at 11:30 a.m. Eastern time on Thursday, April 12, 2007 from the Millennium Broadway Hotel in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)
Dr. Longenecker will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until May 12, 2007.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.CONTACT: Pete De Spain, Director, Investor Relations & CorporateCommunications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com/
